These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 32448085)

  • 21. Virtual screening of quinoline derived library for SARS-COV-2 targeting viral entry and replication.
    Anju A; Chaturvedi S; Chaudhary V; Pant P; Hussain F; Mishra AK
    J Biomol Struct Dyn; 2022 Nov; 40(18):8464-8493. PubMed ID: 34032180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential protease inhibitors and their combinations to block SARS-CoV-2.
    Abhinand CS; Nair AS; Krishnamurthy A; Oommen OV; Sudhakaran PR
    J Biomol Struct Dyn; 2022 Feb; 40(2):903-917. PubMed ID: 32924827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular Binding Mechanism and Pharmacology Comparative Analysis of Noscapine for Repurposing against SARS-CoV-2 Protease.
    Kumar N; Sood D; van der Spek PJ; Sharma HS; Chandra R
    J Proteome Res; 2020 Nov; 19(11):4678-4689. PubMed ID: 32786685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virtual screening of approved clinic drugs with main protease (3CL
    Wang Q; Zhao Y; Chen X; Hong A
    J Biomol Struct Dyn; 2022 Feb; 40(2):685-695. PubMed ID: 32909528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting SARS-COV-2 non-structural protein 16: a virtual drug repurposing study.
    Tazikeh-Lemeski E; Moradi S; Raoufi R; Shahlaei M; Janlou MAM; Zolghadri S
    J Biomol Struct Dyn; 2021 Aug; 39(13):4633-4646. PubMed ID: 32573355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach.
    Sabarimurugan S; Purushothaman I; Swaminathan R; Dharmarajan A; Warrier S; Kothandan S
    Acta Virol; 2021; 65(2):160-172. PubMed ID: 34130467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrated docking and enhanced sampling-based selection of repurposing drugs for SARS-CoV-2 by targeting host dependent factors.
    Kumawat A; Namsani S; Pramanik D; Roy S; Singh JK
    J Biomol Struct Dyn; 2022; 40(20):9897-9908. PubMed ID: 34155961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods.
    Unni S; Aouti S; Thiyagarajan S; Padmanabhan B
    J Biosci; 2020; 45(1):. PubMed ID: 33184246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accelerating the discovery of the beyond rule of five compounds that have high affinities toward SARS-CoV-2 spike RBD.
    Abu-Saleh AAA; Yadav A; Poirier RA
    J Biomol Struct Dyn; 2023 Apr; 41(6):2518-2527. PubMed ID: 35132950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2.
    Al-Khafaji K; Al-Duhaidahawi D; Taskin Tok T
    J Biomol Struct Dyn; 2021 Jun; 39(9):3387-3395. PubMed ID: 32364041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of potential drugs against SARS-CoV-2 non-structural protein 1 (nsp1).
    de Lima Menezes G; da Silva RA
    J Biomol Struct Dyn; 2021 Sep; 39(15):5657-5667. PubMed ID: 32657643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A dynamic simulation study of FDA drug from zinc database against COVID-19 main protease receptor.
    Mathpal S; Joshi T; Sharma P; Joshi T; Pundir H; Pande V; Chandra S
    J Biomol Struct Dyn; 2022 Feb; 40(3):1084-1100. PubMed ID: 32940134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
    Abu-Saleh AAA; Awad IE; Yadav A; Poirier RA
    Phys Chem Chem Phys; 2020 Oct; 22(40):23099-23106. PubMed ID: 33025993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ethnomedicines of Indian origin for combating COVID-19 infection by hampering the viral replication: using structure-based drug discovery approach.
    Alagu Lakshmi S; Shafreen RMB; Priya A; Shunmugiah KP
    J Biomol Struct Dyn; 2021 Aug; 39(13):4594-4609. PubMed ID: 32573351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2'-O-ribose methyltransferase.
    Khan RJ; Jha RK; Amera GM; Jain M; Singh E; Pathak A; Singh RP; Muthukumaran J; Singh AK
    J Biomol Struct Dyn; 2021 May; 39(8):2679-2692. PubMed ID: 32266873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
    Arouche TDS; Martins AY; Ramalho TC; Júnior RNC; Costa FLP; Filho TSA; Neto AMJC
    J Nanosci Nanotechnol; 2021 Apr; 21(4):2075-2089. PubMed ID: 33500022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study.
    Wakchaure PD; Ghosh S; Ganguly B
    J Phys Chem B; 2020 Nov; 124(47):10641-10652. PubMed ID: 33190493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computational studies on phylogeny and drug designing using molecular simulations for COVID-19.
    Nabi F; Ahmad O; Khan YA; Nabi A; Md Amiruddin H; Abul Qais F; Masroor A; Hisamuddin M; Uversky VN; Khan RH
    J Biomol Struct Dyn; 2022; 40(21):10753-10762. PubMed ID: 34278954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An
    Sinha SK; Shakya A; Prasad SK; Singh S; Gurav NS; Prasad RS; Gurav SS
    J Biomol Struct Dyn; 2021 Jun; 39(9):3244-3255. PubMed ID: 32345124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.
    Romeo A; Iacovelli F; Falconi M
    Virus Res; 2020 Sep; 286():198068. PubMed ID: 32565126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.